Cell Therapy CMO Market

The global cell therapy CMO market reached an estimated USD 6.6 billion in 2025, with revenue projected at USD 7.7 billion in 2026 and USD 26.4 billion by 2034. This represents a 16.7% CAGR during 2026–2034. The market measures third-party cell therapy development, manufacturing, release testing and related contract services, rather than sales of the finished therapies themselves.

Third-party manufacturing partners convert investigational living-cell medicines into controlled, traceable doses. Their work includes donor or patient cell receipt, selection, expansion, genetic modification where required, formulation, cryopreservation and batch release. A contract manufacturer may serve a single sponsor at several stages, but the market counts its invoiced service revenue only once. Commercial product sales, research instruments, standalone reagent sales and internal manufacturing expenditure remain outside the service boundary.

Contract demand in 2025 covered both patient-specific autologous manufacturing and donor-derived allogeneic manufacturing, with distinct GMP requirements. Autologous treatments use a patient-specific starting material and demand tightly synchronized collection, manufacturing slots and return shipment. Allogeneic programs process donor-derived material in larger campaigns, but require stringent control of identity, potency, contamination and comparability. Both depend on documented GMP processes; moving a process between facilities can create validation work even when the cellular starting material appears similar.

Established manufacturers are investing in production flexibility rather than treating every project as a standard biologics batch. AGC Biologics added Yokohama cell therapy development and clinical manufacturing in July 2025, alongside Milan and Longmont. Fujifilm completed additional production suites at Thousand Oaks in November 2024. Minaris operates a cell therapy network spanning the United States, Germany and Japan, while Australia-based Cell Therapies supports commercial and investigational products through a Melbourne GMP facility.

Ownership and manufacturing platforms changed across several providers during 2025 and 2026, including Minaris and Rose BioSolutions. The former WuXi Advanced Therapies U.S. and U.K. operations became part of Minaris Advanced Therapies in 2025, and Charles River transferred its CDMO and cell-sourcing business to Rose BioSolutions in May 2026. Automation providers such as Cellares are testing digitally controlled production, while Lonza received an FDA advanced manufacturing technology designation for its Cocoon platform in December 2025. Neither technology designation nor a contract announcement should be confused with product marketing approval.

Source: AGC Biologics Japan expansion; Fujifilm cell therapy suites; Minaris network; Rose BioSolutions transaction.

Revenue comprises third-party contracts for cell therapy process development, GMP cell processing and expansion, clinical or commercial manufacture, integrated release analytics and logistics tied to manufacturing agreements. Services supporting gene-modified cell therapies are included; standalone viral-vector sales and finished therapy product revenue are excluded.

Commercial approvals require repeatable manufacturing capacity

Commercial cell therapy supply depends on validated procedures that can be repeated for every released lot, even when starting material varies by patient. The FDA’s CAR-T guidance addresses chemistry, manufacturing and control as well as clinical development. Contract partners able to document comparability, sterility and potency are therefore better positioned to support later-stage programs. Lonza reported in its 2025 annual materials that all its cell and gene therapy sites had at least one approved commercial program under contract, showing the transition from development work toward repeat production.

Patient-specific scheduling raises operational complexity

Autologous manufacture begins with a time-sensitive apheresis or tissue sample and ends with a product returned to the correct treatment center. Delays at collection, transport, testing or final release can disrupt clinical appointments and reduce usable capacity. Cell Therapies in Melbourne describes validated cryostorage and chain-of-custody arrangements for clinical and commercial programs. The operating model rewards providers that connect quality records, couriers, hospitals and manufacturing teams rather than treating cryogenic logistics as a separate afterthought.

Quality-system investment increases the entry barrier

A cleanroom alone does not qualify a supplier for licensed cell therapy manufacture. Contamination control, electronic records, validated analytical methods and trained personnel must operate as a unified system. Charles River disclosed that its Memphis site had 25 GMP suites and resumed production after facility and quality-system improvements in April 2025. European advanced-therapy GMP rules require a risk-based approach specific to living products. The associated capital and audit obligations favor providers that can maintain stable customer programs through process changes.

Consolidation changes the available supplier network

Ownership transitions can alter contracting, capacity access and technical-transfer plans without immediately changing the physical manufacturing site. The 2025 combination of Minaris Regenerative Medicine with former WuXi Advanced Therapies operations created a broader service network. In May 2026, the Charles River CDMO business moved to Rose BioSolutions under GI Partners ownership. Sponsors evaluating redundancy must distinguish the number of legal vendors from the number of genuinely independent facilities and quality systems available for the same manufacturing process.

Regional regulatory differences complicate cross-border supply

A process transferred between the United States, European Union, Japan and Australia may face different expectations for manufacturing authorization, documentation and batch release. Australia’s TGA requires applicable GMP standards for human cell and tissue products, while the European framework contains tailored advanced-therapy provisions. Sponsors cannot assume that a clinical batch manufactured for one country is automatically acceptable elsewhere. Providers with experienced regulatory staff, comparable assays and established release procedures gain an advantage when clients seek multinational clinical trials or commercial expansion.

Sources: FDA CAR-T guidance; EMA advanced-therapy GMP; TGA manufacturing guidance; Lonza annual report; Charles River Memphis facility disclosure.

Automated closed processing enters clinical manufacture

Automation is being evaluated to reduce manual handling and variability between patient-specific runs. Lonza disclosed FDA Advanced Manufacturing Technologies designation for its Cocoon platform in December 2025, a manufacturing-technology recognition rather than an approval of any therapy. Cellares announced an IND amendment clearance in January 2026 enabling clinical production of investigational rese-cel on its Cell Shuttle system. These examples show why equipment qualification, electronic batch records and process comparability are central purchasing criteria for future outsourced production contracts.

Manufacturers expand across three continents

The manufacturing footprint is becoming more geographically distributed as sponsors seek shorter shipping routes and alternative production sites. AGC Biologics began Yokohama cell therapy services in July 2025, complementing Milan and Colorado. Minaris describes manufacturing operations in New Jersey, Germany and Japan, and Cell Therapies supplies Australian and Asia-Pacific trials from Melbourne. Regional diversification can support clinical enrollment and resilience, but each new location requires staff training, local regulatory readiness and transfer of assays and process specifications.

Approved therapies create multi-year commercial supply work

The supplier relationship extends beyond the initial trial batch when a therapy obtains marketing authorization. In March 2026, Lonza announced an extension of commercial manufacture for ZYNTEGLO at Houston, linking capacity plans to continuing patient demand. RoslinCT disclosed work on Omisirge manufacturing in Massachusetts, including a December 2025 expanded supply arrangement. These commitments demonstrate how licensed therapies can support steady utilization, although signed manufacturing capacity is not identical to recognized annual service revenue and depends on release volumes.

Clinical and commercial service providers reorganize

Specialized manufacturing assets have changed hands as operators concentrate on their preferred modalities. The U.S. and U.K. former WuXi Advanced Therapies businesses were combined with Minaris in 2025, while Rose BioSolutions was formed from the Charles River CDMO and cell-sourcing operations in 2026. Buyers need updated ownership records, technical responsibilities and site histories when issuing tenders. Provider consolidation can strengthen integrated testing capacity but may reduce the apparent independence of a sponsor’s backup supplier network.

Emerging markets invest in local advanced-therapy capacity

Public institutions outside North America and Europe are building capability that may later support independent manufacturing partnerships. Saudi Arabia’s health ministry announced a Riyadh gene and cell therapy facility in October 2025, and Brazilian regulator Anvisa has supported domestic CAR-T development projects. Cell Therapies and South Korea’s ENCell agreed in December 2025 to explore regional manufacturing cooperation. These developments expand the technical base, although hospital-owned or publicly funded in-house manufacturing is not automatically third-party CMO revenue.

Cell therapy CMO services are divided between Stem Cell and Non-Stem Cell projects according to the principal therapeutic cell population. Stem-cell programs include hematopoietic, mesenchymal and induced-pluripotent-cell approaches, while non-stem-cell work includes engineered T cells, natural killer cells and tumor-infiltrating lymphocytes. The distinction determines expansion conditions, release assays and facility scheduling.

Stem-cell and non-stem-cell programs will increasingly share qualified operators and digital records, but they will not share every potency assay or release specification. Facilities able to run different modalities without cross-contamination can improve utilization, provided each customer retains a validated process and documented chain of identity.

Application classifies the intended disposition of the contracted manufacturing work: Commercial, Clinical Trials, Academic Research or Others. A customer may purchase services in several categories over time, but each batch or contracted service is allocated to its purpose at the time it is delivered. This distinguishes launch supply from early development and avoids counting the same work as both trial and commercial revenue.

Application allocations shift when clinical programs receive authorization, enter commercial production or stop after unsuccessful trials. Commercial work creates longer relationships, while clinical contracts supply a flow of new projects and process-development fees. Academic demand remains concentrated near research hospitals and manufacturing innovation centers, where sponsors can obtain technical advice before committing to larger production campaigns.

End User assigns each contract to the paying customer rather than the site where patients receive treatment. Pharmaceutical Companies, Biotech Firms and Research Institutions have different procurement cycles, financing structures and risk tolerances. A therapy may move from a venture-backed developer to a large pharmaceutical owner, changing the end-user classification while the manufacturing facility stays unchanged.

The customer dimension does not equate to a hospital-versus-clinic patient-care split. Hospital-owned treatment centers are counted only when they pay an independent CMO for qualifying work. Ownership transitions and partnerships can change the named buyer without changing the technical manufacturing process, so customer revenue is allocated using the contracting legal entity.

Therapy Area classifies contracts by the intended clinical indication, using Oncology, Neurology, Orthopedics, Cardiovascular and Others. The grouping covers approved cell medicines and investigational work without treating every pipeline candidate as a marketed therapy. Indications determine sponsor priorities, dosing volumes, starting material and the release assays required for each manufactured product.

Oncology should remain the largest revenue pool as licensed treatments and clinical programs require continuing manufacturing services. Expansion into autoimmune and regenerative applications can diversify contract pipelines, but every new indication carries its own clinical evidence and regulatory requirements; manufacturing readiness alone does not establish therapeutic efficacy.

Contract cell therapy manufacturing is concentrated where therapy developers, specialized hospitals, qualified production facilities and regulatory expertise are located. Regional shares measure the location of CMO service revenue rather than the nationality of patients treated with the finished medicine.

Cell therapy contract manufacturing is a fragmented service business in which regulatory track record, process transfer and site-level capability matter more than the breadth of a corporate product catalogue. Lonza, AGC Biologics, Fujifilm and Minaris operate multi-site networks, while RoslinCT, Cell Therapies, Cellares and CellReady emphasize particular cell types or production models. A provider can be qualified for one therapy and still need extensive development work before manufacturing another. Commercial customers therefore evaluate validated process history, analytical capability and the ability to coordinate manufacturing with patient collection and treatment schedules. A signed development agreement does not guarantee a future commercial supply contract.

Fujifilm Diosynth Biotechnologies expanded its Thousand Oaks cell therapy operation with two additional suites in 2024, emphasizing flexible clinical and commercial production. In Australia, Cell Therapies operates from Melbourne with cryogenic storage and validated logistics, and Magellan Stem Cells offers mesenchymal-cell manufacturing under an Australian GMP licence. These regional specialists can reduce transport complexity for local sponsors, although international release requirements still apply. The competition is consequently geographic as well as technical, with sponsors weighing the cost of multiple production sites against the risk of depending on one supplier.

Ownership must be assessed using the May 2026 Rose BioSolutions transaction and the 2025 Minaris combination. The former Charles River CDMO and cell-sourcing assets were acquired by GI Partners and became Rose BioSolutions in May 2026. The U.S. and U.K. WuXi Advanced Therapies business had previously been combined with Minaris. Listing both historical owners and successor entities as independent competitors would overstate the number of suppliers. Cellares, meanwhile, has demonstrated clinical manufacturing on an automated platform, but its commercial manufacturing contracts remain dependent on sponsor development, technical performance and regulatory milestones.

Competition is not determined solely by how many cleanrooms a supplier operates. A facility may have idle space but lack a validated process for a particular cell type, a suitable potency assay or trained personnel for that sponsor. CellReady emphasizes G-Rex-based development and manufacturing, while Resilience markets an Auto-T platform for autologous CAR-T and TCR-T programs. Buyers often prioritize batch reliability, time to release, chain-of-identity controls and audit outcomes above a nominal capacity figure. Providers with transparent deviation management and technology-transfer procedures can build durable relationships with both biotech and pharmaceutical customers.

• Lonza Group AG
• AGC Biologics
• FUJIFILM Diosynth Biotechnologies
• Minaris Advanced Therapies
• RoslinCT
• Rose BioSolutions
• Cell Therapies Pty Ltd
• National Resilience, Inc.
• Cellares
• CellReady
• Magellan Stem Cells

The cell therapy CMO market is projected to grow from USD 7.7 billion in 2026 to USD 26.4 billion in 2034, a 16.7% CAGR. Demand will depend on the number of investigational programs reaching repeat GMP production, the utilization of existing suites and the conversion of clinical manufacturing relationships into commercial supply. Expansion is not automatic: failed trials, quality findings or a sponsor’s decision to build internal capacity can leave specialist facilities underused. The outlook therefore emphasizes operating execution alongside the increasing number of cellular treatment modalities.

The largest revenue contribution should continue to come from mature manufacturing networks in North America and Europe, where sponsors have established relationships with regulators and treatment centers. Commercial cell therapy programs can provide a stable base of recurring production, but their patient volumes are small relative to conventional biologics. Manufacturing organizations must reserve enough capacity for individualized batches without sacrificing flexibility for emerging programs. Providers with several qualified sites may gain contracts from customers seeking geographic redundancy, yet duplication of facilities also increases the cost of maintaining qualified personnel and assays.

Asia-Pacific offers a different growth mechanism: new regional capacity can support local clinical programs and shorten shipping routes for patient material. AGC’s Japanese expansion and the Cell Therapies–ENCell collaboration demonstrate supplier interest in regional networks. This does not mean that every announced facility will generate immediate outsourced revenue. Regulatory authorization, sponsor qualification, process transfer and clinical enrollment must precede reliable service billing. Japan and Australia already have specialized production infrastructure, while additional partnerships may broaden access to manufacturing expertise elsewhere in the region.

Technology will affect cost per successful dose more than simple facility size. Closed processing, automated records and validated quality testing can reduce handling steps, but sponsors still need evidence that their specific cell product remains comparable after process changes. Lonza’s Cocoon designation and Cellares’ clinical manufacturing progress provide examples of technologies moving through formal development pathways. Commercial adoption will require consistent results across multiple batches and clear responsibilities for deviations, sterility testing and chain of identity. Contract pricing will reflect the complexity of these obligations rather than only the number of cells expanded.

The coverage measures outsourced cell therapy services and excludes sponsor sales of licensed therapies, in-house hospital production and unrelated research-equipment revenue.